Characterization of liver disease regression in murine models of liver fibrosis and portal hypertension
Philipp Königshofer(Medical University of Vienna), Thomas Reiberger(ERN GUARD-Heart), Larissa Pfisterer(Boehringer Ingelheim (Germany)), Ksenia Brusilovskaya(Austrian Academy of Sciences), Thomas Sorz(Medical University of Vienna), Benedikt Simbrunner(Austrian Academy of Sciences), Vlad Țâru(Iuliu Hațieganu University of Medicine and Pharmacy), Philipp Schwabl(Austrian Academy of Sciences), Hubert Scharnagl(Medical University of Graz), Katharina Regnat(Medical University of Vienna), Katharina Bonitz(Austrian Academy of Sciences), Oleksandr Petrenko(Austrian Academy of Sciences), Benedikt Hofer(Austrian Academy of Sciences), Michael Trauner(Medical University of Vienna), Katharina Bareiner(Medical University of Vienna), Stefan G. Kauschke(Boehringer Ingelheim (Germany)), Kerstin Zinober(Medical University of Vienna), Tatjana Stojaković
Cited by 0
Related Papers
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
|Annual Review of Pathology Mechanisms of Disease|2018|561
Pathophysiological mechanisms of liver injury in COVID‐19
|Liver International|2020|399